Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06802263 · ClinicalTrials.gov registry record · NA
MIRA CONNECT Study
A NA study of Pregnancy of Unknown Location (PUL), sponsored by University of Colorado, Denver.
- Recruiting
- Registry status
- NA
- Development phase
- 35
- Enrollment target
- 1
- Study location
NCT06802263: Recruiting NA study of Pregnancy of Unknown Location (PUL), sponsored by University of Colorado, Denver.
NCT06802263 is a NA study of Pregnancy of Unknown Location (PUL) that is actively recruiting participants, run by University of Colorado, Denver. The registered enrollment target is 35 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06802263, a NA study of Pregnancy of Unknown Location (PUL), is actively recruiting participants, sponsored by University of Colorado, Denver.
- RECRUITING
- Registry status
- NA
- Development phase
- 35 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this pilot study is to assess the accuracy and precision of an at-home quantitative urine beta hCG (b-hCG) test in the management of pregnancy of unknown location (PUL).
Primary Outcome
Cases will begin performing urine and serum hCG testing 24 hours after the initial hCG level. Urine hCG testing will be performed on the first morning urine at home and participants will limit water for at least 8 hours before testing. Serum hCG testing will occur at a UCHealth laboratory before 10 am and within 2 hours of the urine test to allow for the comparison of the values. Both urine and serum hCG testing will then occur daily x 7 days, or until a medical or surgical intervention is indic
Conditions Studied
Interventions
- DIAGNOSTIC_TEST at-home quantitative urine b-hCG test
Study Locations (1)
Colorado
- University of Colorado - Aurora
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2024-06-01 |
| Est. Completion | 2027-09-30 |
| Phase | NA |
What NCT06802263 shows while recruiting
NCT06802263 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 35 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower).
The record links to 1 condition, with Pregnancy of Unknown Location (PUL) appearing as the primary indexed condition, and to 1 intervention - of which at-home quantitative urine b-hCG test is the first listed.
NCT06802263 reports a single indexed study location in Colorado.
Frequently Asked Questions
What is clinical trial NCT06802263 about?
NCT06802263 is a clinical study titled "MIRA CONNECT Study". The goal of this pilot study is to assess the accuracy and precision of an at-home quantitative urine beta hCG (b-hCG) test in the management of pregnancy of unknown location (PUL).
What is the current status of trial NCT06802263?
This trial is currently recruiting. It is a NA study. The enrollment target is 35 participants. The study started on 2024-06-01. Estimated completion is 2027-09-30.
What conditions does trial NCT06802263 study?
This clinical trial studies the following conditions: Pregnancy of Unknown Location (PUL).
What interventions are being tested in trial NCT06802263?
The interventions under investigation include: at-home quantitative urine b-hCG test (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT06802263?
This trial is sponsored by University of Colorado, Denver, which has 1,283 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06802263 being conducted?
This trial has 1 study location across Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06802263's enrollment target sits among peer trials
35 1564th of 2000 higher than 431 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01697371 · 35 participants · NA
Proton Therapy in the Treatment of Liver Metastases
- NCT01940757 · 35 participants · Phase 1
Experimental Infection of Hookworm-naïve Adults With Dermally-applied Infectious Necator Americanus Hookworm Larvae
- NCT02235857 · 35 participants · NA
Post Approval Study of Liposorber LA-15 System for the Treatment of Focal Segmental Glomerulosclerosis in Children
- NCT02637934 · 35 participants · Phase 1
Phase I Pilot Study of Biodistribution, Metabolism and Excretion of Novel Radiotracer [18F]Fluorthanatrace (FTT) by PET/CT
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI